白塞病合并骨髓异常增生综合征的临床特点(附6例报告)

目的：为了解白塞病（ＢＤ）与骨髓增生异常的相关性。方法：回顾分析了６例ＢＤ合并骨髓异常增生综合征（ＭＤＳ）患者的临床资料、血象和骨髓象。２例合并难治性贫血（ＭＤＳＲＡ），２例合并难治性贫血伴原始细胞增多（ＭＤＳＲＡＥＢ），１例合并转化型难治性贫血伴原始细胞过多（ＭＤＳＲＡＥＢｔ），１例合并慢性粒—单细胞白血病（ＭＤＳＣＭＭＬ）。结果：６例均示有贫血，５例白细胞低下，４例血小板减少。６例骨髓均增生活跃。４例ＢＤ发病在前，２例ＢＤ与ＭＤＳ同时出现。结论：认为ＢＤ与ＭＤＳ有相关性     

净化及非净化自体骨髓移植治疗白血病39例临床研究

报告自体骨髓移植治疗白血病３９例，其中非净化自体骨髓移植（ＡＢＭＴ）１４例，净化自体骨髓移植（ＰＡＢＭＴ）２５例。中位年龄２８岁（１０～４３岁）。ＡＭＬ２７例，ＡＬＬ１０例，ＣＭＬ２例。ＣＲ１３１例，ＣＲ２７例，ＮＲ１例。ＣＲ至移植时间中位数６．７个月（２～１９个月）。预处理方案：ＴＢＩ加Ａｒａ－ｃ、ＤＮＲ或ＶＰ１６。ＡＢＭＴ组及ＰＡＢＭＴ组３年无病生存（ＤＦＳ）率分别为６８．３２％及６７．５７％，复发率为３０．７６％及２６．８０％。但ＰＡＢＭＴ组ＡＭＬ患者３年ＤＦＳ率为８２．３５％及ＣＲ２期移７５％３年ＤＦＳ率为７５％，明显高于ＣＲ。期移植未净化者５０％。化疗组３年ＤＦＳ率为７．３８％及复发率７６．４％，两移植组疗效优于化疗组。     

MDS患者白细胞介素2受体表达研究

本实验以２８例ＭＤＳ（ＲＡ１８例、ＲＡＥＢ和ＲＡＥＢ－Ｔ１０例）和１０例ＡＮＬＬ为研究对象，采用ＡＰＡＡＰ和ＥＬＩＳＡ法检测患者外周血单个核细胞（ＰＨＡ刺激前后）的ＭＩＬ－２Ｒ和培养血清中ＳＴＬ－ＩＲ，结果表明：经ＰＨＡ刺激培养４８ｈ后，ＭＤＳ和ＡＮＬＬ患者Ｔａｃ抗原阳性率明显低于正常人（Ｐ＜０．０１）ＲＡＥＢ和ＲＡＥＢ－ｔ组Ｔａｃ＋率比ＲＡ低，与ＡＮＬＬ差异无显著性（Ｐ＞０．０５）；血清中ＳＴＬ－２Ｒ在ＭＤＳ各亚型中均高于正常对照组（Ｐ＜０．０５），其中以ＲＡＥＢ及ＲＡＥＢ－ｔ为著。认为ＭＤＳ患者免疫反应及监视能减弱；ＳＴＲ－２Ｒ与ｍＩＬ－２Ｒ无相关；ＩＬ－２Ｒ表达异常可能与造血抑制有关。     

细胞凋亡与骨髓增生异常综合征疾病演变的关系

目的探讨骨髓增生异常综合征（ＭＤＳ）骨髓细胞凋亡特征及其病理学意义。方法用原位末端脱氧核糖核苷酸转移酶介导的ｄＵＴＰ缺口末端标记（ＴＵＮＥＬ），ＤＮＡ梯子和体外培养等方法对３８例ＭＤＳ患者骨髓单个核细胞（ＢＭＭＣ）凋亡进行研究。结果ＭＤＳ患者ＢＭＭＣ的ＴＵＮＥＬ凋亡细胞阳性指数（ＰＩ）为２０．１９％±１１．０７％，显著高于正常人、ＭＤＳ转化的白血病、急性髓细胞白血病（ＡＭＬ）及缺铁性贫血（ＩＤＡ）组，（Ｐ＜０．００１和Ｐ＜０．０１）。ＴＵＮＥＬ和ＣＤ４１碱性磷酸酶抗碱性磷酸酶免疫酶标法（ＡＰＡＡＰ）双标记证明ＭＤＳ骨髓病态小巨核细胞发生了凋亡。动态观察１０例ＭＤＳ患者，转为白血病后凋亡细胞ＰＩ值显著下降，尚未转为白血病患者随病情恶化凋亡呈下降趋势。７例ＭＤＳ患者ＢＭＭＣ体外培养后，晚期ＰＩ（ＬＰＩ）显著增高，３例出现ＤＮＡ梯子，ＡＭＬ和ＩＤＡ组ＬＰＩ未见明显升高，未出现ＤＮＡ梯子。结论ＭＤＳ骨髓细胞凋亡过度与演变和转为白血病有关。原位检测细胞凋亡可作为监测ＭＤＳ预后指标     

端粒酶在骨髓增生异常综合征中动态改变的研究

我们用端粒酶序列重复扩增银染法：［１］检测了骨髓增生异常综合征（ＭＤＳ）及转为白血病后的端粒酶活性,探讨端粒酶活性在ＭＤＳ中的临床意义。 一、资料和方法 １．对象：２０例均为我院１９９８年４月～１９９９年１２月的住院或门诊成人患者,初发ＭＤＳ１２例,其中难治性贫血（ＲＡ）３例,原始细胞过多型（ＲＡＥＢ）６例,原始细胞过多转化型（ＲＡＥＢ－Ｔ）２例,慢性粒单核细胞白血病（ＣＭＭＬ）１例,ＭＤＳ转为急性白血病（ＭＤＳ－ＡＬ）８例。２０例中男女各１０例,年龄１８～７６岁,平均年龄４７岁,参照文献［２］而…     

低危骨髓增生异常综合征初诊实验室检查结果与预后及转归的关系

为探讨低危骨髓增生异常综合征（ＭＤＳ）初诊时实验室检查结果与其预后及转归的关系，对９６例低危ＭＤＳ随访观察１２～５５个月。转为ＲＡＥＢ或ＲＡＥＢ－ｔ１０例，转为白血病１６例。死亡２７例，其中１５例死于骨髓衰竭，１２例死于白血病。初诊时外周血血红蛋白＜４０ｇ／Ｌ，血小板＜２０×１０９／Ｌ，中性粒细胞＜０５×１０９／Ｌ，骨髓涂片粒系增生活跃者预后不良；骨髓活检红系增生占优者转白率、病死率低于粒系增生占优者，骨髓造血细胞增生低下者易死于骨髓衰竭，ＡＬＩＰ阳性者转白率及病死率明显高于阴性者。单因素分析结果提示：初诊时实验室检查结果有助于判断低危ＭＤＳ的转归及预后     

自身免疫性肝炎特异性靶抗原的表达及免疫学鉴定

目的 克隆、表达可溶性肝抗原（ＳＬＡ）及细胞色素Ｐ４５０ ２Ｄ６（ＣＹＰ ２Ｄ６）。方法 采用 ＲＴ—ＰＣＲ技术从人肝组织ｐｏｌｙ（Ａ）＋ＲＮＡ中扩增ＳＬＡ及 ＣＹＰ ２Ｄ６ ｃＤＮＡ，经ＢａｍＨ　Ⅰ、Ｈｉｎｄ Ⅲ双酶切定向插入载体ＰＱＥ－３０并在大肠杆菌Ｍ１５中表达。对表达载体ＰＱＥ—３０／ＳＬＡ、ＰＱＥ—３０／ＣＹＰ ２Ｄ６中的目的基因进行序列分析，表达产物用 ＳＤＳ—ＰＡＧＥ、免疫印迹方法鉴定。结果 表达产物经 ＳＤＳ－ＰＡＣＥ和免疫印迹分析后在分子量 ４．７ × １０４和５．０ × １０４处各有一条明显的蛋白带，并分别能特异性与抗ＳＬＡ、ＣＹＰ２Ｄ６阳性血清反应。结论 表达ＳＬＡ、ＣＹＰ２Ｄ６为自身免疫性肝炎的诊断及其发病机制研究提供物质基础。     

SLE病人PBMC分泌IL—6活性水平的研究

为了研究了ＳＬＥ病人ＰＢＭＣ分泌ＩＬ－６的能力，我们采用ＭＴＴ比色法，用ＩＬ－６依赖细胞株（７ＴＤ１）分别测定了１５例活动期，１５例非活动期ＳＬＥ病人和１５例正常对照者ＰＢＭＣ培养上清ＩＬ－６的活性水平。结果表明ＳＬＥ患者ＰＢＭＣ自发分泌ＩＬ－６的水平显著高于正常人（Ｐ〈０．０２或Ｐ〈０．００１），活动期患者高于非活动期患者（Ｐ〈０．００１）。ｐＨＡ－Ｍ刺激培养体系后，ＳＬＥ患者及正常人ＰＢＭＣ培     

骨髓增生异常综合征患者T细胞受体基因重排的检测价值

目的 为了解骨髓增生异常综合征（ＭＤＳ）患者Ｔ细胞受体（ＴＣＲ）基因重排情况。方法 应用聚合酶链反应检测３６例ＭＤＳ患者ＴＣＲＶγＩ－Ｊγ基因重排。结果 ８例（２２．２％）ＭＤＳ患者检测出克隆性ＴＣＲＶγＩ－Ｊγ基因重排;难治性贫血伴有原始细胞增多（ＲＡＥＢ）,慢性粒－单细胞白血病（ＣＭＭＬ）和转化中的ＲＡＥＢ（ＲＡＥＢ－Ｔ）组ＴＣＲＶγＩ－Ｊγ基因重排阳性ＭＤＳ转化为急性白血病时间显著短于重排阴     

抗恶性疟原虫有性期单克隆抗体的制备和鉴定

以培养的恶性疟原虫ＮＦ５４（３Ｄ７）株配子体蛋白抽提液及我国云南现场采集的恶性疟原虫细胞骨架分别免疫ＢＡＬＢ／ｃ小鼠。取免疫小鼠脾细胞与ＳＰ２／０骨髓瘤细胞融合，以ＩＦＡ法筛选出８株抗恶性疟原虫有性期ＭｃＡｂ杂交瘤细胞株。经免疫球蛋白类别鉴定，６株为ＩｇＧ１（Ｍ２Ａ１０Ｃ９、Ｍ２Ｃ１Ｂ８、Ｍ４Ｃ７Ｂ１０、Ｍ４Ｇ１２Ｃ１、Ｍ５Ｂ７Ｅ６和Ｍ６Ｅ１Ｇ１１），２株为ＩｇＭ（Ｍ４Ｄ７Ｆ７和Ｍ６Ｆ４Ｄ６）。其     

Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.

Marrow cells from 36 patients with myelodysplastic syndromes (MDS) (13 refractory anemia [RA], 14 refractory anemia with excess of blasts [RAEB], 9 RAEB in transformation [RAEB-T]) were evaluated for their in vitro proliferative and differentiative responsiveness to recombinant human granulocyte colony-stimulating factor (G-CSF) or granulocyte-monocyte CSF (GM-CSF). GM-CSF exerted a stronger proliferative stimulus than G-CSF for marrow myeloid clonal growth (CFU-GM) in these patients (44 v 12 colonies per 10(5) nonadherent buoyant bone marrow cells [NAB], respectively, P less than .025). GM-CSF stimulated increased CFU-GM growth in the 16 patients with abnormal marrow cytogenetics in comparison with the 20 patients who had normal cytogenetics (52 and 30 colonies per 10(5) NAB, respectively, P less than .05), whereas no such difference could be demonstrated with G-CSF (11 and 16 colonies per 10(5) NAB, respectively). In contrast, granulocytic differentiation of marrow cells was induced in liquid culture by G-CSF in 15 of 32 (47% patients), while GM-CSF did so in only 4 of 18 (22%) patients (P less than .025) including, for RAEB/RAEB-T patients: 9 of 18 versus 0 of 9, respectively (P less than .025). For MDS patients with normal cytogenetics, G-CSF- and GM-CSF-induced marrow cell granulocytic differentiation in 12 of 18 (67%) versus 3 of 11 (27%), respectively (P less than .025), contrasted with granulocytic induction in only 3 of 14 (21%) and 1 of 7 (14%) patients with abnormal cytogenetics, respectively. We conclude that G-CSF has greater granulocytic differentiative and less proliferative activity for MDS marrow cells than GM-CSF in vitro, particularly for RAEB/RAEB-T patients and those with normal cytogenetics.     

Treatment of myelodysplastic syndromes with all-trans retinoic acid. Leukemia Study Group of the Ministry of Health and Welfare

We treated 23 patients with myelodysplastic syndromes (MDS); 2 refractory anemia (RA) with prior therapy, 11 RA with excess of blasts (RAEB), and 10 RAEB in transformation (RAEB-T), with daily oral 45 mg/m2 all-trans retinoic acid (ATRA) in a multiinstitutional prospective study. In two patients with RAEB and one with RAEB-T, a more than 1,000/microL increase of peripheral neutrophil counts was observed with some reduction of blast percentage in the bone marrow 2 to 9 weeks after the start of ATRA. However, the effect was transient and did not last for more than 5 weeks despite the continuation of ATRA therapy. In one other patient with RA, one patient with RAEB, and one patient with RAEB-T, slight increase of hemoglobin levels or reduction of blast percentage in bone marrow was noted. Toxicities attributable to ATRA were minimal and included cheilitis, xerosis, dermatitis, gastrointestinal disorders, abnormal liver function tests, and high serum triglyceridemia. Although ATRA works remarkably as a differentiation therapy in acute promyelocytic leukemia, its effect in MDS included in this study was modest. Further study of this agent alone or in combination may be warranted in less advanced stages of this disease.     

Myeloablative conditioning for marrow transplantation in myelodysplastic syndromes and paroxysmal nocturnal haemoglobinuria

Paroxysmal nocturnal haemoglobinuria (PNH) and myelodysplastic syndromes (MDS) are disorders of pluripotent stem cells resulting in haematopoietic insufficiency which can be cured by marrow transplantation. The extent of myeloablative conditioning necessary for elimination of the non-malignant and premalignant clones is not known. We report our results of marrow transplantation with and without myeloablative conditioning in two patients with PNH and seven patients with MDS. Conditioning was not used in a patient with PNH and a monozygotic twin as donor. In this patient the disease remained unchanged. Myeloablative treatment with busulphan (BUS) in addition to immunosuppression with cyclophosphamide (CY) was used for conditioning in a patient with PNH and a 2-year-old boy with chronic myelomonocytic leukaemia (CMML). Fractionated total body irradiation (FTBI) and CY was used in six patients with refractory anaemia with excess of blasts (RAEB) and RAEB in leukaemic transformation (RAEB-T). Haematopoiesis was fully restored in all patients conditioned with myeloablative treatment except for a patient in leukaemic transformation with myelofibrosis and a HLA-DR-incompatible donor. Chimerism was complete in all patients except for the 2-year-old boy conditioned with BUS and CY. Our results and those reviewed in the literature indicate that myeloablative conditioning with either BUS or FTBI is advantageous for marrow transplantation in PNH and MDS.     

Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience

The purpose of this study was to evaluate the role of allogeneic bone marrow transplantation (BMT) in children with myelodysplastic syndrome (MDS). In total, 94 consecutive pediatric patients with MDS received an allogeneic BMT from 1976 to 2001 for refractory anemia (RA) (n=25), RA with ringed sideroblasts (RARS) (n=2), RA with excess blasts (RAEB) (n=20), RAEB in transformation (RAEB-T) (n=14), juvenile myelomonocytic leukemia (JMML) (n=32) or chronic myelomonocytic leukemia (CMML) (n=1). The estimated 3-year probabilities of survival, event-free survival (EFS), nonrelapse mortality and relapse were 50, 41, 28 and 29%, respectively. Patients with RA/RARS had an estimated 3-year survival of 74% compared to 68% in those with RAEB and 33% in patients with JMML/CMML. In multivariable analysis, patients with RAEB-T or JMML were 3.9 and 3.7 times more likely to die compared to those with RA/RARS and RAEB (P=0.005 and 0.004, respectively). Patients with RAEB-T were 5.5 times more likely to relapse (P=0.01). The median follow-up among the 43 surviving patients is 10 years (range 1-25). We conclude that allogeneic BMT for children with MDS is well tolerated and can be curative.     

Immunotyping of blasts in refractory anaemia with excess of blasts

Summary. A study of immunological markers was performed in 16 patients with newly diagnosed refractory anaemia with excess of blasts (RAEB) and RAEB in transformation (RAEB-T) and in 12 other patients with acute myeloid leukaemia evolving from RAEB or RAEB-T. Immunocytochemical investigation of bone marrow blasts was done using a modified indirect immunoperoxidase technique. This method permitted accurate morphological identification of blasts and other cells in bone marrow. The monoclonal antibodies used in RAEB and RAEB-T samples were anti-CD34, -c-kit, -HLA-DR and -CD13.
The range of CD34 expression of blasts in RAEB samples was 1–14% (mean 6·2%) and in RAEB-T samples 29–48% (mean 35·5%). CD34 positivity was detected in 3·94% (mean 47·4%) of the bone marrow blasts in acute myeloid leukaemia evolving from RAEB and RAEB-T. Expression of c-kit was demonstrated only in a low percentage of blast cells in RAEB, RAEB-T and acute myeloid leukaemia following myelodysplasia. A high percentage (> 30%) of blasts in most patients with RAEB, RAEB-T and acute myeloid leukaemia was HLA-DR and CD13 positive. We observed the transformation from RAEB to acute myeloid leukaemia in three patients. The proportion of CD34 positive blasts increased to 25% and 32% in two patients. The third patient showed an unchanged percentage of CD34 positivity of blasts.
These findings indicate that the CD34 positivity of blasts increases with the progression of myelodysplasia to RAEB-T and acute myeloid leukaemia demonstrating the instability of the clonal defect in myelodysplasia.     

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

Forty-nine patients with primary myelodysplastic syndromes (MDS) were subclassified according to French-American-British (FAB) Cooperative Group criteria. Eight patients had acquired idiopathic sideroblastic anemia (AISA), ten had chronic myelomonocytic leukemia (CMMoL), 14 had refractory anemia (RA), nine had refractory anemia with excess blasts (RAEB), and five had refractory anemia with excess blasts in transformation (RAEB-T); three patients could not be subclassified. The actuarial median survival for patients with AISA or with RA had not been reached at 60 months of follow-up. The median survival times for patients with CMMoL, RAEB, and RAEB-T were 25, 21, and 16 months, respectively. The percentages of patients with each subtype who developed ANLL were none in AISA, 20% in CMMoL, 7% in RA, 56% in RAEB, and 40% in RAEB-T. Patients with CMMoL had a poor prognosis independent of transformation to acute nonlymphocytic leukemia (ANLL), whereas patients with RAEB and RAEB-T had a high incidence of transformation and short survival times. Clonal chromosomal abnormalities were present in bone marrow cells from 19 patients at the time of diagnosis, and two others developed an abnormal karyotype at the time of leukemic transformation. The most frequent abnormalities, including initial and evolutionary changes, were trisomy 8 (9 patients), deletion of 5q (4 patients), and deletion of 20q (4 patients). The median survival times were 32 months for patients with an abnormal karyotype, and 48 months for those with a normal karyotype (P = 0.2). Specific chromosomal abnormalities were not associated with particular histologic subtypes; however, a high percentage of patients with RAEB and RAEB-T had an abnormal clone (89% and 80%, respectively). The percentages of patients with clonal abnormalities were 13% for AISA, 20% for CMMoL, and 29% for RA. The MDS transformed to ANLL in 42% of patients with an abnormal karyotype, compared to 10% of those with an initially normal karyotype (P less than .01). Among patients with RA, RAEB, and RAEB-T, the risk of leukemic transformation was confined to those with an abnormal karyotype (P less than .01). Thus, in the present study, morphology and karyotype combined were the best indicators of outcome in patients with MDS.     

Differential cellular expression of the human MSH2 protein in normal and myelodysplastic haematopoiesis

Loss of human MSH2 (hMSH2) protein might be involved in the multistep pathogenesis of haematological malignancies associated with genetic instability. Here, we examine cellular hMSH2 expression in bone marrow samples from 10 haematopoietically normal individuals in comparison with nine patients with myelodysplastic syndrome (MDS) [one refractory anaemia (RA), two RA with ringed sideroblasts (RARS), four RA with excess blasts (RAEB) and two RAEB in transformation (RAEB-T)]. HMSH2 protein was predominantly expressed in myeloblasts and promyelocytes. Blast cells from three patients with RAEB and one with RAEB-T displayed absent or very low hMSH2 expression. As no correlation between hMSH2 expression and chromosomal aberrations was observed, further genetic events seem to be required to induce karyotype instability.     

Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis

An analysis of clinical, haematological, histological and cytogenetic data was performed in 85 consecutive patients with myelodysplastic syndromes (MDS). The criteria for diagnosis of refractory anaemia (RA), acquired idiopathic sideroblastic anaemia (AISA) and chronic myelomonocytic leukaemia (CMML) were clearly defined, since the inclusion criteria provided by the FAB co-operative group are imprecise. None of these patients has received chemotherapy during the follow-up period. The median survival of the whole group was only 15 months, with less than 10% of the patients surviving after 5 years. Fifteen patients (17.6%) were still alive at time of analysis, 31 (36.5%) have developed acute myeloid leukaemia (AML) and only one of them is still alive; 30 (35.3%) died of infectious and/or haemorrhagic complications. Patients who developed AML had a shorter survival (median survival time 9.5 versus 15 months) but this difference was not significant (P = 0.10). Factors with prognostic value are in order of significance: abnormal localized immature myeloid precursors (= ALIP) in the trephine biopsy, circulating myeloblasts, excess of blasts in the bone marrow smears, age, FAB classification and granulocyte count. In comparison to refractory anaemia with excess of blasts (RAEB), CMML and RAEB in transformation (RAEBt), patients with RA and AISA had a lower incidence of evolution to AML (11% versus 56%), but a higher mortality rate from infections and/or bleeding (59.2% versus 29%). ALIP negative cases were only found among patients with RA and AISA, whereas ALIP positivity was observed in all cases of RAEB and RAEBt, in 10/11 patients with CMML and in almost half the cases of RA and AISA. In RA and AISA patients survival was significantly different between ALIP positive and ALIP negative cases (P = 0.009). Among MDS patients, ALIP negative cases developed significantly less AML than ALIP positive cases (5% versus 44%), but a similar percentage of mortality from infectious and/or haemorrhagic complications was seen in both groups (33% versus 36.5%). Chromosomal analysis proved to be of no significant prognostic value, although a trend for shorter survival was observed in patients with complex karyotype anomalies or without mitoses. Because of their prolonged survival, antileukaemic chemotherapy is contra-indicated in ALIP negative patients (median survival 50 months). Nevertheless they only constitute a minor subgroup of MDS cases. Prognosis in ALIP positive patients is poor (median survival 12.5 months); in these patients therapeutic trials with cytostatic drugs or with inducers of differentiation of myeloid precursor cells seem to be justified.     

Primary myelodysplastic syndromes: diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies.

Material from 63 cases with primary myelodysplastic syndromes (P-MDS) (French-American-British [FAB] types: refractory anemia [RA] = 21; RA with ring sideroblasts [RARS] = 8; RA with excess of blasts (RAEB) = 10; RAEB in transformation (RAEBt) = 6; chronic myelomonocytic leukemia [CMML] = 10 and unclassifiable = 8, ie, bone marrow aspiration was inadequate and stringent FAB criteria were not applicable) was analyzed for bone marrow histologic and immunohistochemical patterns. Standard Giemsa, hematoxylin and eosin (H&E) and reticulin stains were used for morphologic assessment. To identify the cell lineage precisely, chloroacetate esterase staining and an indirect immunoperoxidase technique using mouse monoclonal antibodies CD15, CD68, HLA-DR, and rabbit polyclonal CD3 and UEA-1 (lectin) was developed on formalin-fixed paraffin embedded bone marrow biopsies (BMB). The immunohistochemical assessment permitted accurate identification of dysplastic features such as mononuclear and binuclear megakaryocytes, Pelger-Huet neutrophils, and binuclear erythroblasts. Additional bone marrow histologic and immunohistochemical features observed were heterogeneity of immunohistochemical staining in various cell lineages, megakaryocytic emperipolesis, alteration of bone marrow microarchitecture, intravascular clusters of hematopoietic cells, and the types of benign lymphoid aggregates. The nature of abnormally localized immature precursors (ALIP) was discerned. Three types of clusters of immature cells were found that were difficult to distinguish on Giemsa and H&E morphology, these were erythroid aggregates (n = 18); megakaryocytic aggregates (n = 4), and immature granulocytic and monocytic aggregates (n = 32). The bone marrow histologic and immunohistologic patterns permitted the identification of four groups of clinical relevance: Group 1, cases with predominant erythroid hyperplasia and without ALIP (n = 15); group 2, cases with prominent myeloid hyperplasia and presence of ALIP (n = 32); group 3, cases with hypoplastic MDS (n = 10); and group 4, cases with hyperfibrotic MDS (n = 6). Statistical analysis showed a significant difference in survival and leukemic transformation between groups 1, 2, 3, and 4, with cases in group 2 showing the worst prognosis with early death due to increased propensity to leukemic transformation and cytopenia-related complications (P less than .0001). We conclude that immunohistochemistry is feasible on routinely processed BMB and the information obtained is of diagnostic and prognostic importance in P-MDS. The phenotype of ALIP varies with the morphologic and histologic subtypes of MDS and the term should be reserved for cases in whom the clusters in the intertrabecular region are of myeloid (granulocytic and monocytic) lineage on immunohistochemistry.     

骨髓增生异常综合征T细胞早期激活及可溶性肿瘤坏死因子受体的研究

目的　研究骨髓增生异常综合征 (MDS)外周血CD+ 4 、CD+ 8T细胞早期激活标志CD69的表达及血清、骨髓可溶性肿瘤坏死因子受体 1、2 (sTNF R1、2 )的水平及其意义。方法　在植物血凝素 (PHA) 2 0mg/L条件下进行全血细胞培养 ,于 0h和 4h分别用流式细胞仪对CD+ 4 、CD+ 8T细胞CD69的表达进行分析。用ELISA法检测血清和骨髓sTNF R1、2的水平。结果　PHA刺激前难治性贫血 (RA)与难治性贫血伴环形铁粒幼细胞增多 (RAS)CD+ 4 、CD+ 8细胞CD69的表达率分别为 8 32 %、9 88% ,难治性贫血伴原始细胞增多 (RAEB)与转变中的RAEB(RAEB T)CD+ 8细胞CD69的表达率为7 92 %。PHA刺激后MDS患者CD+ 4 、CD+ 8细胞表达CD69明显增强 ,RA +RAS为 5 3 4 6 %、5 1 6 3% ;RAEB +RAEB T为 4 2 93%、4 1 96 % ,CD+ 4 与CD+ 8细胞CD69的表达率相似。MDS两种sTNF R1水平均明显升高 ,RA +RAS组sTNF R1血清为 (1 5 8± 0 6 8) μg/L ,骨髓为 (2 10± 0 2 6 ) μg/L ;sTNF R2血清为 (1 4 1± 0 5 0 ) μg/L ,骨髓为 (1 95± 0 6 4 ) μg/L ;RAEB +RAEB T组sTNF R1血清为 (2 6 2± 2 5 5 ) μg/L ,骨髓为 (3 12± 0 6 7) μg/L ;sTNF R2血清为 (1 96± 0 5 6 ) μg/L ,骨髓为(3 0 9± 0 6 2 ) μg/L。血清sTNF R2水平与PHA刺激